Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53

Journal of the National Cancer Institute

Volumn 101, Issue 22, 2009, Pages 1562-1574

  Van Maerken, Tom ^a   Ferdinande, Liesbeth ^a   Taildeman, Jasmien ^a   Lambertz, Irina ^b   Yigit, Nurten ^a   Vercruysse, Liesbeth ^a   Rihani, Ali ^a   Michaelis, Martin ^c   Cinatl, Jindrich ^c   Cuvelier, Claude A ^a   Marine, Jean Christophe ^b   De Paepe, Anne ^a   Bracke, Marc ^a   Speleman, Frank ^a   Vandesompele, Jo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE ARREST; CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASPASE 3; CASPASE 7; CELL CYCLE; CELL LINE, TUMOR; DIPLOIDY; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MUTATION; NEUROBLASTOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449727603     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp355     Document Type: Article

References (61)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007 ; 369 (9579): 2106-2120.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999 ; 17 (7): 2264-2279.
3. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001 ; 61 (16): 6185-6193.
4. Xue C, Haber M, Flemming C, et al. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 2007 ; 67 (21): 10351-10360.
5. Carr J, Bell E, Pearson AD, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res. 2006 ; 66 (4): 2138-2145.
6. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 ; 325 (23): 1608-1614.
7. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996 ; 334 (4): 231-238.
8. Blanc E, Goldschneider D, Ferrandis E, et al. MYCN enhances P-gp/ MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol. 2003 ; 163 (1): 321-331.
9. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol. 2006 ; 24 (10): 1546-1553.
10. Anderson CP, Seeger RC, Satake N, et al. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol. 2001 ; 23 (8): 500-505.
11. Yang B, Keshelava N, Wan Z, et al. Glutathione (GSH) and RNA expression of GSH synthetic and utilization enzymes are increased in drug-resistant neuroblastoma cell lines. Proc Am Assoc Cancer Res. 2003 ; 44: 1273.
12. Emran MA, Rebbaa A, Mirkin BL. Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells. Cancer Lett. 2002 ; 182 (1): 53-59.
13. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002 ; 62 (22): 6462-6466.
14. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007 ; 67 (2): 735-745.
15. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is signifi cantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000 ; 19 (5): 617-623.
16. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg. 2006 ; 41 (8): 1431-1440.
17. Dole M, Nunez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994 ; 54 (12): 3253-3259.
18. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 2001 ; 61 (12): 4864-4872.
19. Friesen C, Fulda S, Debatin KM. Defi cient activation of the CD95 (APO-1/ Fas) system in drug-resistant cells. Leukemia. 1997 ; 11 (11): 1833-1841.
20. Yang X, Merchant MS, Romero ME, et al. Induction of caspase 8 by interferon 7 renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 2003 ; 63 (5): 1122-1129.
21. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett. 2005 ; 228 (1-2): 133-141.
22. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic effi cacy of p53 restoration in tumors. Cell. 2006 ; 127 (7): 1323-1334.
23. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007 ; 445 (7128): 656-660.
24. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007 ; 445 (7128): 661-665.
25. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 ; 303 (5659): 844-848.
26. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006; 66 (19): 9646-9655.
27. Cinatl J Jr, Cinatl J, Kotchetkov R, et al. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Anticancer Res. 2000 ; 20 (2A): 853-859.
28. Michaelis M, Cinatl J, Anand P, et al. Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett. 2007 ; 250 (1): 107-116.
29. Vandesompele J, De Paepe A, Speleman F. Elimination of primer-dimer artifacts and genomic coamplifi cation using a two-step SYBR green I realtime RT-PCR. Anal Biochem. 2002 ; 303 (1): 95-98.
30. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003 ; 31 (1): 122-123.
31. Pattyn F, Robbrecht P, De Paepe A, Speleman F, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res. 2006 ; 34 (Database issue): D684-D688.
32. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantifi cation framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8 (2): R19.
33. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002 ; 3 (7): research0034.
34. Willems E, Leyns L, Vandesompele J. Standardization of real-time PCR gene expression data from independent biological replicates. Anal Biochem. 2008; 379 (1): 127-129.
35. Kotchetkov R, Driever PH, Cinatl J, et al. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol. 2005 ; 27 (4): 1029-1037.
36. Blaheta RA, Daher FH, Michaelis M, et al. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer. 2006 ; 6: 294.
37. Combaret V, Audoynaud C, Iacono I, et al. Circulating MYCN DNA as a tumor-specifi c marker in neuroblastoma patients. Cancer Res. 2002 ; 62 (13): 3646-3648.
38. Gotoh T, Hosoi H, Iehara T, et al. Prediction of MYCN amplifi cation in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005 ; 23 (22): 5205-5210.
39. Hoffmann-La Roche. A study of R7112 in patients with advanced solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US) ; 2000. http://clinicaltrials. gov/show/NCT00559533. Accessed September 9, 2009. NLM Identifi er: NCT00559533.
40. Hoffmann-La Roche. A study of R7112 in patients with hematologic neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US) ; 2000. http://clinicaltrials. gov/show/NCT00623870. Accessed September 9, 2009. NLM Identifi er: NCT00623870.
41. Johnson & Johnson Pharmaceutical Research and Development. L.L.C. A research study of JNJ-26854165 to determine the safety and dose in patients with advanced stage or refractory solid tumors. In: ClinicalTrials. gov [Internet]. Bethesda MD: National Library of Medicine (US) ; 2000. http://clinicaltrials. gov/show/NCT00676910. Accessed September 9, 2009. NLM Identifi er: NCT00676910.
42. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009 ; 49: 223-241.
43. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006 ; 103 (6): 1888-1893.
44. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005 ; 65 (5): 1918-1924.
45. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol. 2006 ; 2 (4): 202-206.
46. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006 ; 107 (10): 4109-4114.
47. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuro-blastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 ; 5 (9): 2358-2365.
48. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther. 2006 ; 5 (2): 411-417.
49. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 2007 ; 26 (24): 3473-3481.
50. Graat HC, Carette JE, Schagen FH, et al. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther. 2007 ; 6 (5): 1552-1561.
51. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab. 2007 ; 8 (4): 395-403.
52. Ribas J, Boix J, Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res. 2006 ; 312 (12): 2394-2400.
53. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res. 2007 ; 5 (11): 1133-1145.
54. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009 ; 100 (6): 1128-1136.
55. Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway syn-ergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther. 2008 ; 7 (5): 1101-1109.
56. Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008 ; 22 (9): 1728-1736.
57. Secchiero P, Melloni E, di Iasio MG, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood. 2009 ; 113 (18): 4300-4308.
58. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006 ; 5 (23): 2778-2786.
59. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008 ; 112 (7): 2886-2895.
60. Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009 ; 15 (3): 933-942.
61. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 2007 ; 67 (7): 3210-3219